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Available online 8 October 2016AbstractPolycyclic Aromatic Hydrocarbons (PAHs) are potent carcinogens. Among these, dimethylbenz(a)anthracene (DMBA) is well known for its
capacity to induce mammary carcinomas in female Sprague-Dawley (SD) rats. Ovariectomy suppresses the susceptibility of this model to
DMBA, thus suggesting that the inducible action of the carcinogen depends on ovarian hormones. The promotion of DMBA-induced adeno-
carcinoma is accompanied by a series of neuroendocrine disruptions of both Hypothalamo-Pituitary-Gonadal (HPG) and Hypothalamo-Pituitary-
Adrenal (HPA) axes and of the secretion of melatonin during the latency period of 2 months that precedes the occurrence of the first mammary
tumor. The present review analyses the various neuroendocrine disruptions that occur along the HPG and the HPA axes, and the marked
inhibitory effect of the carcinogen on melatonin secretion. The possible relationships between the neuroendocrine disruptions, which essentially
consist in an increased pre-ovulatory secretion of 17b-estradiol and prolactin, associated with a marked reduction of melatonin secretion, and the
decrease in gene expression of the receptors for aryl-hydrocarbons receptor (AhR) and 17b-estradiol (ERa; ERb) are also discussed.
© 2016 The Authors. Published by Elsevier B.V. on behalf of Socie´te´ Franc¸aise de Biochimie et Biologie Mole´culaire (SFBBM). This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Keywords: Mammary cancer; Neuroendocrine disruption; Dimethylbenz(a)anthracene; Female rat
Contents
1. Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 50
2. The ovarian cycle of the female rat . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 50
3. DMBA, the brain and Hypothalamo-Pituitary axes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 50
3.1. Disruption of the Hypothalamo-Pituitary-Gonadal (HPG) axis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 51
3.2. Disruption of the Hypothalamo-Pituitary-Adrenal (HPA) axis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 52
3.3. Disruption of the secretion of melatonin from the pineal gland . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 52
4. The mechanisms of action triggered by DMBA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 53
4.1. DMBA: an estrogen-mimetic in the short-term? . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 53
4.2. DMBA: acting negatively on receptor function in the long-term? . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 53Abbreviation list: ACTH, Adrenocorticotropic hormone; AhR, Aryl hydrocarbon Receptor; ARNT, AhR nuclear translocator; CRH, Corticotropin releasing
hormone; CYP, Cytochromes P450; DMBA, Dimethylbenz(a)anthracene; E2, 17b-estradiol; ERa and ERb, Estrogen receptor; FSH, Folliculo-Stimulating Hormone
GnRH, Gonadotropin-Releasing Hormone; HPA, Hypothalamo-Pituitary-Adrenal; HPG, Hypothalamo-Pituitary-Gonadal; LH, Luteinizing hormone; PAHs, Poly-
cyclic Aromatic Hydrocarbons; PRL, Prolactin; SD, Sprague-Dawley; TCDD, 2,3,7,8-tetrachlorodibenzo-p-dioxin; XRE, Xenobiotic response elements.
* Corresponding author.
E-mail address: bernard.kerdelhue@parisdescartes.fr (B. Kerdelhue).
1 Universite Paris Descartes, Sorbonne Paris Cite, Paris, France.
http://dx.doi.org/10.1016/j.biopen.2016.09.003
2214-0085/© 2016 The Authors. Published by Elsevier B.V. on behalf of Socie´te´ Franc¸aise de Biochimie et Biologie Mole´culaire (SFBBM). This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).;
50 B. Kerdelhue et al. / Biochimie Open 3 (2016) 49e554.3. DMBA: a complex action on two receptors subsets? . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 53
5. Conclusion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 54
6. Conflict of interest: . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 54
Acknowledgements . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 54
References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 541. Introduction
A large number of polycyclic Aromatic Hydrocarbons
(PAHs) have been identified as potent carcinogens and/or
endocrine disruptors. PAHs are widely distributed in the
environment as a result of incomplete combustion of fossil
fuels and other organic molecules and are common contami-
nants of terrestrial and aquatic ecosystems [1,2 and therein].
Numerous compounds of the PAH family have been associated
with the development of tumors in humans and experimental
animals [3 and therein]. Among these, dimethylbenz(a)
anthracene (DMBA) was extensively used as a model to study
the molecular mechanisms of mammary carcinogenesis in
Sprague-Dawley (SD) female rats [4]. Of particular interest is
the observation that a single intra-gastric dose of DMBA is
sufficient to induce mammary adenocarcinoma in contrast to
the archetypal PAHs, benzo(a)pyrene or 3-methyl-cholanthrene
for which the administration of several doses are needed [4].
The induction of mammary tumors by DMBA in rats is
well documented. After metabolic activation in the mammary
gland [5], the metabolites of the carcinogen interact with
rapidly proliferating cells in the terminal end buds, forming
DNA adducts and subsequent mutations, which in turn play a
role in their transformation to malignant cells [6e8]. DMBA is
a highly lipophilic molecule. The breast contains significant
amount of adipose tissue, in which DMBA can concentrate at
the epithelium contact before its metabolic activation and this
property certainly correlates with the higher activity of DMBA
at the mammary level. Other PAHs certainly act along the
same line of events.
Sprague-Dawley (SD) rats are DMBA-sensitives, with a
peak of susceptibility at 55e60 days of age. Ovariectomy
suppresses this susceptibility, suggesting that the inducible
action of the carcinogen is related to ovarian hormones and the
ovarian cycle [9].
The promotion of DMBA-induced adenocarcinoma is
accompanied by a series of neuroendocrine disruptions of the
Hypothalamo-Pituitary-Gonadal (HPG) and Hypothalamo-
Pituitary-Adrenal (HPA) axes and of the secretion of mela-
tonin during the latency period of 2 months that precedes the
occurrence of mammary tumors. The aim of this review is to
report on the various neuroendocrine disruptions occurring
along the closely interconnected HPG and HPA axes, and to
analyze the marked effect of the carcinogen on melatonin
secretion and their influence on the carcinogenic process [10].
The potential relationships between these neuroendocrine
disruptions and the observed effects on the expression of thegenes coding for the Aryl hydrocarbon Receptor (AhR) and
for both estrogen receptors (ERa and ERb), are also discussed.
2. The ovarian cycle of the female rat
The ovarian cycle of the female rat is much shorter (4-days)
than that in the woman (28-days). However, the 2 major
events, the follicular and the luteal phases, occurring during
the 4-days cycle in the female rat are a simple reduction in
time of the same events occurring during the 28-days cycle in
the woman.
In the female rat, the duration of the follicular phase is of 2
days versus 14 days in the woman. The follicular phase is
characterized by the secretion of the Folliculo-Stimulating
Hormone (FSH) in the blood, which in turn, stimulates the
secretion of 17b-estradiol (E2). At the end of that phase, a pre-
ovulatory surge of E2 occurs which triggers pre-ovulatory
surges of hypothalamic Gonadotropin-Releasing Hormone
(GnRH), pituitary Luteinizing Hormone (LH), FSH and Pro-
lactin(PRL). The surges of LH and FSH are provoked by the
surge of the hypothalamic GnRH in the Hypothalamo-
Pituitary portal blood system. The pre-ovulatory LH surge
provokes the ovulation of the mature follicle. The luteal phase
lasts 2 days in the female rat, versus 14 days in the woman and
is characterized by the secretion of progesterone in response to
the secretion of LH.
Another important difference between the ovarian cycles of
the female rat and that of the woman is the absence of
menstruation in the rodent. For that reason, the cycle of the
female rat is named estrous and the cycle of the woman is
named menstrual. In addition, there is no pre-ovulatory PRL
surge during the menstrual cycle of the woman.
3. DMBA, the brain and Hypothalamo-Pituitary axes
After one single administration (15 mg/rat by gastric intu-
bation), DMBA is able to cross the blood-brain barrier and to
induce the expression of cytochromes P450 (CYP) in endo-
thelial cells of blood brain interfaces [10]. Furthermore,
labeled [H3]-DMBA and its metabolites have been identified
in different area of the brain, including the hypothalamus, the
pituitary gland, the pineal gland and the frontal cortex (Can-
onico M, Lenoir V and Kerdelhue B, unpublished results). In
addition, DMBA disorganizes the neuronal plasma membranes
in rat hypothalamus [11]. This pollutant is then able to disrupt
the physiological processes regulated by those brain structures,
including Hypothalamo-Pituitary axes.
Fig. 1. The 17b-estradiol, Luteinizing hormone (LH) and prolactin surges in female Wistar rats, a DMBA-insensitive strain (up), and in female Sprague-Dawley
rats, a DMBA-sensitive strain (bottom) in the afternoon of the proestrus at any estrous cycle after treatment.
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(HPG) axisIn female SD rats, a DMBA-sensitive strain, DMBA
significantly inhibited LH and FSH surges and stimulated the
PRL and the E2 surges in the afternoon of the proestrus at any
estrous cycle after treatment [12,13] (Fig. 1, Table 1). No
difference was found for LH, FSH and PRL or E2 concen-
trations in the blood at other times of the estrous cycle. In
addition, no difference was found for the level of any other
anterior pituitary hormone at any time of the estrous cycle. InFig. 2. mRNA expression of the AhR, ERa and ERb genes in the hypothacontrast, in female Wistar rats, a DMBA-resistant strain, the
pre-ovulatory or basal LH, FSH, PRL and E2 secretions were
not modified at any time of the estrous cycle after treatment
with the carcinogen (Fig. 1). There was also no reported dif-
ference for any other pituitary hormone at any time of the
estrous cycle [12,13]. The pituitary gland is not the only area
affected by DMBA exposure: ovariectomized SD rats that
were pre-treated with DMBA exhibited a reduced GnRH
release, as measured in vitro using synaptosomes from the
mediobasal hypothalamus, together with a blunted in vivo LH
release in response to E2 [14]. In addition, disturbances of thelamus and the pineal gland after one single administration of DMBA.
Fig. 3. The neuro-endocrine mechanisms of action triggered by DMBA on both Hypothalamo-Pituitary-Adrenal and Hypothalamo-Pituitary-Gonadal axes in the
SD female rat: DMBA alters melatonin secretion by the pineal gland, the secretion of GnRH and CRH by the hypothalamus which eventually impacts the pituitary
(secretion of FSH, LH, PRL and ACTH), adrenal gland (secretion of corticosterone) and ovary functions (secretion of E2) and the feedback loops.
52 B. Kerdelhue et al. / Biochimie Open 3 (2016) 49e55expression of the GnRH and its pituitary receptor genes
occurred throughout the estrus cycle [15]. The early and
persistent alterations in the hypothalamic centers that were
involved in the neuroendocrine cyclicity of the HPG axis very
likely resulted from a direct action of DMBA.
In pre-menopausal women, the development of breast
cancer is associated with reduced plasma GnRH and of FSH
secretion in post menopausal women, thus suggesting the
existence of neuroendocrine disruptions in the woman that
could be involved in tumor promotion and that could be
mimicked in a sensitive rat model with a single dose of a
common PAH [16].Table 1
A summary of the DMBA effects on several neuroendocrine axes.
Hypothalamus ANT.
pituitary
Pineal
gland
Ovary Adrenal
gland
AhR 20% 20%
ER-alpha 15% 20%
ER-beta 25% 20%
GnRH þ30%
CRH 20%
LH 30%
FSH 20%
PRL þ30%
Melatonin 70%
17b-E2 þ20%
Corticosterone 60%3.2. Disruption of the Hypothalamo-Pituitary-Adrenal
(HPA) axisThe HPA axis includes the hypothalamus that secretes
corticotropin releasing hormone (CRH) which stimulates the
release of adrenocorticotropic hormone (ACTH) from the pi-
tuitary gland, thus allowing the secretion of glucocorticoids
from the adrenal cortex. Glucocorticoids control stress re-
actions, the digestive and immune system, mood and emotions,
sexuality, and energy storage and expenditure. Along the HPA
axis, a long-term disregulation of the circadian and E2-induced
corticosterone secretion was observed in DMBA-treated rats
[17] (Table 1). The most important disregulation observed after
administration of DMBA, is the almost complete abolition of
the circadian rhythm of plasma corticosterone. This fact could
be responsible for the change in the behavior of female rats in
preparation for mammary cancers. In an open space system,
DMBA-treated female rats exhibit a long-term reduction of
anxiety level after treatment with the mammary carcinogen
[18]. A relationship between breast cancer and stress response
has been documented in the woman [Ref. in [19]].3.3. Disruption of the secretion of melatonin from the
pineal glandMelatonin is a well-documented hormone secreted in a
circadian fashion by the pineal gland and is implicated in
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and release of melatonin is driven by the suprachiasmatic
nucleus of the hypothalamus [21].
A single intragastric administration of DMBA to SD female
rats induces a long-term marked decrease in the spontaneous
and norepinephrine-induced melatonin secretion from the pi-
neal gland, in an in vitro perfusion system (Table 1) [22].
Melatonin secretion was completely blunted when E2 was
present in the perfusion medium, even at a low and physio-
logical concentration (1010 M) [22]. In contrast, the E2
antagonist tamoxifen, stimulated melatonin secretion [22].
Last but not least, melatonin had a preventive and curative
effect on the mammary carcinogenesis induced by DMBA
[23].
In the woman, it can be envisioned that the long-term in-
hibition of melatonin secretion by ovarian steroids might play
a major role during the promotion phase of the mammary
carcinogenesis. Whether or not a similar decrease in the
secretion of melatonin from the pineal gland could be gener-
ated in the woman by non-identified carcinogenic environ-
mental factors and therefore could constitute a promotional
factor for breast cancer remains to be proven. Nevertheless, a
disruption of melatonin secretion provoked by rotating night
shifts increases the risk of breast cancer in the woman [24]. In
addition, low levels of urinary melatonin have been associated
with an increased risk of breast cancer in premenopausal
women and increased melatonin levels have been related to a
lower risk of invasive breast cancer in postmenopausal women
[25]. In this context, any modification of melatonin secretion
under the influence of breast cancer carcinogens should be
placed under scrutiny.
The cellular and molecular actions of melatonin in relation
with breast cancer have been well documented (ref in
[26,27]); melatonin oncostatic action is mainly due to its anti-
estrogenic action involving the estrogen receptor alpha (ERa)
(ref. in [28]).
4. The mechanisms of action triggered by DMBA
To summarize (Fig. 3), DMBA disrupts several key factors
of both Hypothalamo-Pituitary axes in SD female rats: 1) along
the HPG axis, we could hypothesize that the decreased
expression of GnRH (and its secretion by the hypothalamus)
and pituitary GnRH-R partly explains the blockade of LH and
FSH surges and the maintenance of high E2 blood concentra-
tions. It is noteworthy that PRL secretion by the pituitary gland
is increased (which is consistent with the fact that PRL
secretion does not depend on GnRH); 2) along the HPA axis,
DMBA probably counteracts the effect of E2 on corticosterone
secretion and abolishes almost completely the circadian
secretion of the latter hormone. 3) In the melatoninergic sys-
tem, DMBA and E2 act similarly for the blunting of the
secretion of this hormone.
Overall, DMBA seems to exert pro- and anti-estrogenic
effects on the neuroendocrine system, that can be partly
explained by recent data and the direct/indirect effects of this
carcinogen on several key cellular receptors, including theestrogen receptors (ERs) and the Aryl hydrocarbon Receptor
(AhR), which have been shown to interact [29]. The AhR is a
transcription factor, expressed in the central nervous system
(including the hypothalamus, the hippocampus & the pitui-
tary) [30]. Upon ligand binding (mostly xenobiotics), the AhR
translocates to the nucleus where it heterodimerizes with the
AhR nuclear translocator (ARNT) and the complex binds to
xenobiotic response elements (XRE), regulating positively or
negatively the transcription of target genes, including those
encoding detoxification enzymes [31].4.1. DMBA: an estrogen-mimetic in the short-term?DMBA was previously shown to mimic neuroendocrine
effects of E2 [11,32]. These effects were very likely provoked
by the binding of DMBA to ERs or to the AhR (or to both
receptors since an intrinsic function of the AhR was docu-
mented as a possible key factor in female reproduction) [33].
Several studies showed that E2 down-regulated the expression
of both GnRH and GnRH-R genes [15]. We could then hy-
pothesize that DMBA acts similarly to E2 along the HPG axis,
wherein it binds to ERs and subsequently delays the secretion
of GnRH induced by the hypothalamus and the pituitary FSH/
LH surges.4.2. DMBA: acting negatively on receptor function in the
long-term?After one single administration of DMBA and although
this xenobiotic is not a persistent organic pollutant, a long
lasting and similar decrease in the expression of AhR, ERa
and ERb genes in the hypothalamus and the pineal gland was
observed (Fig. 2) [34]. No change in the expression of
the above-mentioned genes occurred in the hippocampus, a
non-neuroendocrine structure [34]. In view of the well-
documented action of estrogens on both HPG and HPA axes
and of the strong interconnections between those two axes
[35], the decrease in expression of the ERa and ERb genes
are very likely responsible for the constant disregulations of
the HPG and HPA axes. We could then hypothesize that the
E2-induced corticosterone secretion along the HPA axis,
could be impacted on the long-term by the action of DMBA
on the expression of ER [15].4.3. DMBA: a complex action on two receptors subsets?Since DMBA is a polycyclic aromatic hydrocarbon and
AhR ligand, we can hypothesize that, like most AhR ligands,
it displays anti-estrogenic properties [36,37]. For example,
female SD rats that were treated with TCDD (2,3,7,8-
tetrachlorodibenzo-p-dioxin), an AhR high affinity ligand,
display delayed incidence of mammary tumors [38]. Only a
limited number of studies were carried out on the nervous
system of mammals with DMBA but alternative ligands,
including TCDD, were sometimes used [39]. Experimental
studies showed that animals exposed to AhR ligands dis-
played multiple symptoms including defects of motor
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regulated by estrogens and ERs [40e43]. The interplay be-
tween the AhR and ERs is indeed quite complex: 1) AhR
ligands decrease E2 blood concentration and stimulate the
expression of both cytochromes P450 1A1 and 1B1 that use
E2 as a substrate [30,44,45]. 2) AhR exerts a competitive
action on ERs, using the same transcriptional co-activators
(CBP/p300) [39]. 3) Inhibitory XREs have been character-
ized in the promoters of estrogen-responsive genes [46]. 4)
AhR triggers the ubiquitination and degradation of ERa
(forming a nuclear complex with CUL4B, an E3-ubiquitin
ligase) [47]. However, pro-estrogenic properties could also
be observed with unbound ER; AhR could then act as a co-
activator on the promoter of estrogen-responsive genes [45].
In line with these observations, several studies showed a co-
localization of the AhR and the ERs in the central nervous
system; for example, a co-localization of the AhR with ERb
in the anterior pituitary [32] and the brain (Ref. in [38]) was
described.
5. Conclusion
Besides its well-documented carcinogenic action at the
mammary gland level, DMBA provokes long-term and con-
stant neuroendocrine disruptions of the functioning of two
major neuroendocrine axes, the HPG and the HPA. Several
observations might be important to give a clue for the carci-
nogenesis process. First, the secretion of melatonin is reduced
by DMBA (and E2) while the preventive and curative effects
of melatonin on breast cancer are well known. Second, along
the HPG axis, the increased DMBA-induced secretion of E2
and PRL favors the promotion of the mammary cancer while,
along the HPA axis, the reduced secretion of corticosterone
and the marked reduction of the circadian rhythm might ac-
count for the long-term reduction of anxiety level during the
promotion phase of the mammary cancer.
Globally, several hypotheses could be enunciated regarding
the consequences of ER and AhR down-regulation in both
hypothalamus and pituitary structures. On a short-term
mechanism of action, DMBA mimics E2 because it binds to
E2R, but also stimulates a negative feedback loop through
AhR activation, thus explaining the occurrence of pro- and
anti-estrogenic effects. It is noteworthy that, following long-
term exposure to DMBA, AhR mRNA is down regulated,
thus suggesting that the global picture is far more complex
than expected and requests additional investigations. Epige-
netic mechanisms could also take place to explain the long-
lasting effect of DMBA and needs to be explored because it
could represent a novel type of cross-talks between AhR and
ERs.
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